Valeant Pharmaceuticals (VRX) has notable insider buying

Valeant Pharmaceuticals (T:VRX)

Thomas Appio, a Senior Officer, acquired 12,230 Common Shares on a direct ownership basis at a price of $9.710USD through an exercise of rights on May 10th, 2017. This represents a $118,753 investment into the company's shares and an account share holdings change of greater than 100%.

Richard Urbain De Schutter, a Director, acquired 20,000 Common Shares on a direct ownership basis at a price of $13.900USD through the public market on May 11th, 2017. This represents a $278,000 investment into the company's shares and an account share holdings change of 86.8%.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.